We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Novel Diagnostic Technique Could Revolutionize Identification of Pathogens in Biological Samples

By LabMedica International staff writers
Posted on 26 Apr 2023

In cases where a patient suffers from an infection, particularly in their bloodstream, traditional methods can take up to seven days to identify pathogens. More...

This delay impedes prompt and accurate diagnosis and treatment, negatively affecting the patient's prognosis. A similar lag occurs in cell therapy product manufacturing, where it can take seven to 14 days to detect contaminants like bacteria, viruses, and fungi. As cell therapy products cannot be sterilized, early contaminant detection is crucial to restart the production cycle, ensuring the safe and prompt delivery of these products to patients.

A research team from the Singapore-MIT Alliance for Research and Technology (SMART, Singapore) is developing an innovative diagnostic method capable of quickly identifying low-abundance pathogens in biological samples. In prior research, the team developed electrostatic microfiltration as an efficient sample preparation device for bacteria enrichment. Their current goal is to integrate this microfilter with mainstream detection methods, allowing for bacterial detection using digital loop-mediated isothermal amplification—a type of polymerase chain reaction (PCR). The resulting system will be fast, single-use, portable, and user-friendly, eliminating the need for a highly specialized facility. Additionally, it will be compatible with other advanced downstream detection techniques and can easily be incorporated into existing commercial kits or facilities to enhance detection method performance.

“This project builds on on-going projects at SMART focused on separating viruses and bacteria – which are much smaller than mammalian cells – from biological samples, and could revolutionize the way pathogens are identified,” said Dr. Yaoping Liu, Senior Postdoctoral Associate at SMART CAMP, who is leading the research team. “The use of an efficient and relatively cost-effective method could significantly improve the prognosis of sepsis and other infectious diseases, and allow the delivery of timely and more personalized care.”

Related Links:
SMART 


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.